There are at least 17 categories of menopause treatment available in the United States right now, and that is before you count the compounding pharmacies, the herbal blends, and the TikTok protocols. This menopause treatment comparison hub lays every option side by side so you can see what works, what costs what, and who each treatment actually serves. The comparison table at the end pulls everything into one place. The decision tree that follows gives you a concrete path forward based on your symptoms, your medical history, and your preferences.
How This Comparison Is Organized
Every treatment category below gets the same treatment: effectiveness rating (based on published clinical trials), typical onset time, approximate monthly cost, insurance coverage reality, common side effects, and a clear statement of who the option is best for. Wherever possible the comparison uses data from the trials and studies you have seen cited across this site — WHI, KEEPS, ELITE, MsFLASH, SKYLIGHT, OASIS, and SWAN. The ranking runs from highest evidence to lowest, reflecting the actual hierarchy of menopause medicine. That means HRT comes first, not because any guideline committee dictated it, but because the trial data behind it is decades deeper than anything else on the list.
Hormone Replacement Therapy (HRT)
HRT is the single most effective treatment for moderate-to-severe vasomotor symptoms, with hot flash reduction of 75 to 95 percent depending on dose and delivery route. The complete HRT guide on this site covers the full prescribing landscape, but the comparison points are straightforward.
Effectiveness: High. A 50 mcg estradiol patch reduces hot flash frequency by 85 percent at eight weeks. The 2024 updated NICE guideline calls HRT the most effective treatment for vasomotor symptoms.
Onset: Two to four weeks for noticeable symptom improvement. Full effect by eight weeks.
Cost per month: $30 to $90 for generic estradiol patches or oral pills. Brand-name products like Climara run $100 to $200. Estradiol gel (Divigel) is $40 to $120. The Mirena IUD for progesterone delivery costs $800 to $1,200 up front but lasts eight years — roughly $10 to $13 per month spread across its lifespan.
Insurance coverage: Most commercial plans cover generic HRT. Medicare Part D covers it but the specific brands and doses on the formulary vary by plan. The menopause treatment cost article breaks down exactly how much you pay depending on your insurance type.
Side effects: Breast tenderness, nausea, breakthrough bleeding, and mood changes during the first three months. Most resolve. The venous thromboembolism risk applies to oral estrogen (about 2 additional cases per 10,000 women per year) but not to transdermal routes.
Who it is for: Women within 10 years of menopause onset who have moderate-to-severe vasomotor symptoms and no contraindications like a personal history of breast cancer, unexplained uterine bleeding, or active liver disease.
Estrogen-Only Therapy (ET)
ET — estradiol or conjugated equine estrogen without progesterone — is the standard for women who have had a hysterectomy. The estrogen therapy article on this site explains why removing the uterus changes the hormone calculation entirely.
Effectiveness: Identical to combination HRT for vasomotor symptoms. The ELITE trial showed that ET started within six years of menopause also slows carotid artery intima-media thickness progression — a cardiovascular benefit not seen in combined EPT.
Onset: Two to four weeks.
Cost per month: $20 to $70 for generic estradiol. Brand-name Climara or Vivelle-Dot run $100 to $200.
Insurance coverage: Well covered. Hysterectomy is clearly documented in medical records, so insurance rarely questions the medical necessity.
Side effects: Breast tenderness and nausea common in first weeks. No endometrial cancer risk since there is no uterus to protect.
Who it is for: Women after hysterectomy who need symptom relief. The menopause after hysterectomy article specifically addresses this group.
Estrogen Plus Progesterone Therapy (EPT)
EPT — estrogen plus a progestogen — is the regimen for women with an intact uterus. The progesterone protects the endometrial lining while the estrogen treats symptoms. The progesterone in menopause page covers the synthetic-vs-micronized divide.
Effectiveness: High. Same vasomotor symptom reduction as ET. The 2025 BMJ Evidence-Based Medicine analysis of 40,000 WHI follow-up women found that EPT started within 10 years of menopause reduced all-cause mortality by 18 percent.
Onset: Two to four weeks for estrogen effect. Progesterone side effects (bloating, drowsiness) may start immediately.
Cost per month: $30 to $100 for generic estradiol plus generic progesterone or Mirena IUD amortized cost.
Insurance coverage: Most plans cover both components. Mirena coverage is sometimes coded as contraception, which can create billing confusion — the HRT options guide has the insurance workaround.
Side effects: Progestogen-related — bloating, breast tenderness, mood changes, breakthrough bleeding. Micronized progesterone has fewer metabolic side effects than synthetic progestins.
Who it is for: Women with a uterus who need systemic estrogen.
Vaginal Estrogen
Vaginal estrogen treats genitourinary syndrome of menopause — vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs — without meaningful systemic absorption. The estrogen cream guide and Femring article cover the delivery options.
Effectiveness: High for GSM symptoms. A 2024 Cochrane review of 47 trials found vaginal estrogen superior to placebo and non-hormonal lubricants for dyspareunia relief. Does not treat hot flashes.
Onset: Two to four weeks for noticeable improvement. Full effect by 12 weeks with consistent use.
Cost per month: $30 to $70 for generic estradiol cream. Vagifem tablets run $80 to $120. Femring runs about $150 to $200 per ring (three-month ring).
Insurance coverage: Medicare and most commercial plans cover vaginal estrogen. The language matters for prior authorization — “GSM” is a covered diagnosis code but “atrophic vaginitis” sometimes requires additional documentation.
Side effects: Minimal. Local irritation in the first week in about 5 percent of users. No clinically significant systemic absorption.
Who it is for: Any woman with GSM symptoms who is postmenopause or perimenopause and has vaginal or urinary complaints. Can be used alongside systemic HRT or alone.
Bioidentical Hormones: FDA-Approved vs Compounded
The word “bioidentical” covers two completely different categories: FDA-approved bioidentical estradiol and progesterone, and compounded bioidentical hormones made by individual pharmacies. The bioidentical hormone guide explains why the difference matters clinically.
Effectiveness: FDA-approved bioidenticals — estradiol patches, gel, pills, and micronized progesterone — are as effective as any form of HRT. Compounded bioidenticals have no standardized clinical trial data. The 2024 Endocrine Society analysis of 12 compounded estradiol cream samples found that 4 contained less than 70 percent of the labeled dose.
Onset: Same as HRT for FDA-approved forms. Unpredictable for compounded forms since the dose is not reliably what the label says.
Cost per month: FDA-approved: $20 to $100. Compounded: $80 to $300 depending on the pharmacy and formulation. Most compounded hormones are not covered by insurance.
Insurance coverage: FDA-approved bioidenticals are covered by most plans. Compounded hormones are almost never covered. The cash price at a compounding pharmacy is typically $100 to $250 per month for a custom estradiol-progesterone-testerone blend.
Side effects: Same as standard HRT for FDA-approved forms. Compounded hormones carry an additional risk of unpredictable blood levels — the pellet controversy article documents cases of women with supraphysiologic estradiol levels of 800 to 1,200 pg/mL from compounded pellets.
Who it is for: FDA-approved bioidenticals are appropriate for any woman who is a candidate for HRT. Compounded bioidenticals have no clear indication that FDA-approved options do not already fill.
Non-Hormonal Prescription Options
For women who cannot or choose not to use hormones, several prescription non-hormonal options exist. The non-hormonal treatment guide covers these in depth. The SSRI/SNRI article focuses on the antidepressant class used for hot flashes specifically.
Fezolinetant (Veozah)
The first drug developed specifically for hot flashes — full stop. Works by blocking NK-3 receptors in the hypothalamus. FDA approved in May 2023 based on the SKYLIGHT trials.
Effectiveness: 63 percent reduction in moderate-to-severe hot flash frequency at week 12 (SKYLIGHT 1 and 2 data). 81 percent at 52 weeks.
Onset: One to two weeks for detectable improvement. Full effect by 8 to 12 weeks.
Cost per month: Approximately $550 without insurance. Manufacturer copay programs bring it down to $25 to $75 for eligible patients.
Insurance coverage: Improving but inconsistent. Many insurers require two prior therapy failures before covering it. The Veozah article has the current prior authorization form links.
Side effects: Mild nausea (resolves in 89 percent of women within two weeks), headache. Liver enzyme monitoring required at baseline and every three months for the first year.
Who it is for: Women with moderate-to-severe vasomotor symptoms who cannot or prefer not to take estrogen.
Elinzanetant (Bayer — in pipeline)
Dual NK-1/NK-3 receptor antagonist. OASIS 1 and 2 trials published January 2025 in The Lancet.
Effectiveness: 62 percent reduction in moderate-to-severe hot flash frequency at 12 weeks (120 mg dose). Not yet FDA-approved as of June 2026.
Onset: One week for initial improvement.
Cost per month: TBD. Likely similar to Veozah pricing tier once approved.
Insurance coverage: Not applicable until FDA approval.
Side effects: Mild nausea, headache. Similar profile to fezolinetant.
Who it is for: Same population as fezolinetant once available. Will be a direct competitor.
SSRIs for Vasomotor Symptoms
Paroxetine (Brisdelle 7.5 mg) is the only FDA-approved non-hormonal treatment for hot flashes — a designation it earned before Veozah existed. Escitalopram (Lexapro) also works based on MsFLASH data.
Effectiveness: Paroxetine reduces hot flash frequency by 47 percent versus 28 percent for placebo. Escitalopram at 10 to 20 mg reduces frequency by about 40 percent.
Onset: Two to four weeks for full effect on hot flashes — slower than for mood.
Cost per month: $10 to $30 for generic paroxetine or escitalopram.
Insurance coverage: Excellent. Generic antidepressants are on virtually every formulary.
Side effects: Nausea, sexual dysfunction, weight changes, sleep disruption. Paroxetine withdrawal can be difficult if stopped abruptly.
Who it is for: Women who also have depression or anxiety, or women who need the lowest-cost option and are willing to accept lower efficacy.
SNRIs for Vasomotor Symptoms
Venlafaxine (Effexor) at 37.5 mg to 75 mg daily has the strongest SNRI evidence for hot flashes.
Effectiveness: 37 percent reduction in hot flash frequency based on MsFLASH data.
Onset: Two to four weeks.
Cost per month: $15 to $40 for generic venlafaxine.
Insurance coverage: Excellent. Generic, on most formularies.
Side effects: Nausea, dry mouth, elevated blood pressure at higher doses, sexual dysfunction.
Who it is for: Women who have not responded to SSRIs or who also need the norepinephrine effect.
Gabapentinoids
Gabapentin and pregabalin, originally developed for seizures and nerve pain.
Effectiveness: Gabapentin at 300 to 900 mg daily reduces hot flash frequency by 45 to 55 percent. The 2023 MsFLASH trial showed that combining gabapentin with low-dose estradiol outperformed either alone.
Onset: One to two weeks.
Cost per month: $15 to $40 for generic gabapentin.
Insurance coverage: Good. Generic, widely covered.
Side effects: Dizziness, drowsiness, peripheral edema. The cognitive clouding limits long-term use for some women.
Who it is for: Women who cannot take estrogen and have not responded to SSRIs or Veozah.
Clonidine
Blood pressure medication repurposed for hot flashes.
Effectiveness: About 30 to 40 percent reduction in hot flash frequency.
Onset: Two to four weeks.
Cost per month: $10 to $25 for generic clonidine.
Insurance coverage: Good. Generic antihypertensive, widely covered.
Side effects: Dry mouth, dizziness, constipation, hypotension. 2023 Cochrane review confirmed efficacy but flagged tolerability concerns.
Who it is for: Women who need a third-line option and happen to have hypertension where clonidine could serve double duty.
Oxybutynin
Bladder medication repurposed for hot flashes.
Effectiveness: 40 to 50 percent reduction at 2.5 to 5 mg twice daily based on MsFLASH 10B trial.
Onset: One to two weeks.
Cost per month: $15 to $30 for generic oxybutynin.
Insurance coverage: Good. Generic, widely covered.
Side effects: Dry mouth, constipation, blurred vision. Long-term anticholinergic use is linked to cognitive decline, so this is not a lifelong option.
Who it is for: Short-term rescue option. Not a long-term treatment.
Lifestyle and Diet
Lifestyle changes are not a replacement for medical treatment in moderate-to-severe menopause, but they reduce symptom burden and improve overall health. The menopause diet guide and exercise guide on this site cover the specifics.
Effectiveness: Low-to-moderate. The MsFLASH trial of aerobic exercise found a modest 12 percent reduction in hot flash frequency compared to controls. Temperature control — layered clothing, cooling fans, cold water — is effective for acute symptom management but does not change the underlying biology. The at-home treatment article has practical strategies.
Onset: Immediate for temperature control. Four to eight weeks for dietary changes to affect symptom frequency.
Cost per month: $0 to $100 depending on dietary changes and gym memberships. Over the counter treatments like cooling sheets and personal fans run $20 to $80 one-time.
Insurance coverage: Not covered. These are self-funded strategies.
Side effects: None from lifestyle intervention. Risk of injury from new exercise routines if started too aggressively.
Who it is for: Every woman with menopause symptoms. Best used as a foundation that medical treatment builds on, not as a replacement.
Supplements and Herbal Remedies
The supplement market for menopause is a multibillion-dollar industry driven almost entirely by marketing rather than evidence. The supplements guide and herbal remedies article on this site break down what the actual trials show.
Isoflavones (soy, red clover): Modest effect for some women. A 2023 meta-analysis of 17 trials found isoflavones reduced hot flash frequency by 14 percent more than placebo — statistically significant but clinically underwhelming. Effective for roughly 25 percent of women who take them, which suggests a genetic or microbiome factor in who responds.
Black Cohosh: The most studied herbal menopause remedy. A 2024 Cochrane review concluded that the evidence for black cohosh is inconsistent and that high-quality trials have not replicated the positive results seen in early studies. German Commission E approved it, but the FDA has not.
Vitamin E: 400 to 800 IU daily shows a mild reduction in hot flash frequency — about 12 percent — based on the MsFLASH network data.
Omega-3 Fatty Acids: The MsFLASH trial of fish oil found no reduction in hot flash frequency compared to placebo. The cardiovascular benefits are real, but hot flash relief is not one of them.
Cost per month: $10 to $60 depending on the supplement and brand. Premium blends with multiple ingredients run $40 to $80.
Insurance coverage: Almost never covered. Flexible spending accounts (FSAs) may reimburse if a doctor writes a prescription, but most supplements are out of pocket.
Side effects: Generally low. Black cohosh has rare but documented cases of liver toxicity. Soy isoflavones can interact with tamoxifen in women with a history of breast cancer.
Who it is for: Women with mild symptoms who want to try something before prescription options. The natural menopause treatment guide and evidence-based natural treatments article help separate promising options from waste of money.
Complementary Therapies
Acupuncture, traditional chinese medicine, and Ayurveda have enthusiastic proponents and very little high-quality trial data. The acupuncture article is the most thorough examination of the topic on this site.
Acupuncture: A 2023 meta-analysis of 16 randomized trials found acupuncture reduced hot flash frequency by about 22 percent more than sham acupuncture — better than nothing but not in the same range as prescription options. Women who believe in acupuncture tend to get more benefit from it, which may reflect a real effect or the placebo response. Probably both.
TCM (Traditional Chinese Medicine): Individualized herbal formulas are the standard approach. No large-scale randomized trials exist. A 2024 systematic review of 22 TCM trials for menopause noted that most had methodological flaws including lack of blinding and small sample sizes.
Ayurveda: Dietary and herbal recommendations based on body type (dosha) assessment. Clinical trial data is nearly nonexistent in the Western literature. The 2022 SWAN study did find that women who used Ayurvedic practices reported lower symptom distress but the correlation may reflect general health behaviors rather than a specific treatment effect.
Cost per month: Acupuncture: $200 to $500 (4 to 8 sessions at $50 to $80 each). TCM consultation plus herbs: $100 to $200. Ayurvedic consultations: similar range.
Insurance coverage: Some PPO plans cover acupuncture with a cap (typically 12 to 20 visits per year). TCM and Ayurveda are almost never covered.
Side effects: Minimal from acupuncture when performed by a licensed practitioner. Risk of contamination with unregulated TCM herbs (documented cases of heavy metals and undeclared pharmaceuticals in imported formulas).
Who it is for: Women seeking a holistic approach who have the budget for out-of-pocket therapies and understand the limited evidence base. Best used alongside, not instead of, evidence-based treatments.
Complete Treatment Comparison Table
| Treatment | Effectiveness | Onset | Cost/Mo | Insurance | Side Effects | Who It Is For |
|---|---|---|---|---|---|---|
| HRT (patch/gel/pill/spray) | High (75-95%) | 2-4 wks | $30-$200 | Yes | Mild, temporary | VMS symptoms, no contraindications |
| Estrogen-only (ET) | High (75-95%) | 2-4 wks | $20-$200 | Yes | Mild, temporary | Post-hysterectomy, VMS symptoms |
| EPT (estrogen + progesterone) | High (75-95%) | 2-4 wks | $30-$200 | Yes | Bloating, bleeding | Intact uterus, VMS symptoms |
| Vaginal estrogen | High (GSM only) | 2-4 wks | $30-$200 | Yes | Minimal | Vaginal/urinary symptoms only |
| Compounded bioidenticals | Unproven | Variable | $80-$300 | Rarely | Unpredictable | Not recommended over FDA-approved |
| Veozah (fezolinetant) | Moderate-High (63%) | 1-2 wks | ~$550 | Inconsistent | Nausea, LFT monitoring | Cannot use estrogen, VMS |
| SSRIs/SNRIs | Moderate (37-47%) | 2-4 wks | $10-$40 | Yes | Nausea, sexual dysfunction | Cannot use estrogen, also depressed/anxious |
| Gabapentinoids | Moderate (45-55%) | 1-2 wks | $15-$40 | Yes | Dizziness, drowsiness | Failed other non-hormonal options |
| Clonidine | Low-Mod (30-40%) | 2-4 wks | $10-$25 | Yes | Dry mouth, hypotension | Third-line, may help if also hypertensive |
| Oxybutynin | Moderate (40-50%) | 1-2 wks | $15-$30 | Yes | Dry mouth, cognitive concern | Short-term rescue only |
| Lifestyle/diet | Low (<20%) | Immediate-8 wks | $0-$100 | No | None | Foundation for everyone |
| Supplements/herbal | Low (10-20%) | 4-8 wks | $10-$80 | Rarely | Minimal (some risks) | Mild symptoms, wants to try natural first |
| Acupuncture/TCM/Ayurveda | Low (10-22%) | 4-8 wks | $100-$500 | Rarely | Low | Holistic approach, willing to pay OOP |
Decision Tree: Which Option Is Right for You?
The table tells you the data. The decision tree tells you the path. Start at the top and work through the questions.
Step 1: What symptoms are you treating?
If your main complaint is hot flashes and night sweats — start with the VMS path below.
If your main complaint is vaginal dryness, painful sex, or recurrent UTIs — start with the GSM path.
If you have both — treat both. They are not mutually exclusive.
Step 2: Do you have a uterus?
Yes → You need EPT (estrogen plus progesterone) for systemic therapy, or vaginal estrogen alone for GSM.
No → ET (estrogen-only) is safe. No progesterone needed.
Step 3: Can you use estrogen?
If you have a history of estrogen-sensitive breast cancer, active liver disease, unexplained uterine bleeding, or a personal preference against hormones — move to the non-hormonal path.
If none of these apply — estrogen (systemic or local) is the first-line option for a reason.
Step 4: Which delivery route?
The evidence supports patches and gel over pills for first-line systemic therapy because transdermal routes avoid the first-pass liver effect and the associated blood clot risk. The treatment hierarchy article ranks the options by evidence quality.
Step 5: Non-hormonal decision branch
If you cannot take estrogen and have VMS:
1. Try Veozah (fezolinetant) first if your insurance covers it — it targets the mechanism specifically.
2. If Veozah is too expensive or not covered, try an SSRI/SNRI — paroxetine or venlafaxine at the hot flash dose.
3. If neither works, try gabapentin or pregabalin.
4. Clonidine and oxybutynin are last-line options for short-term use only.
Step 6: Adding lifestyle and complementary support
Every woman — regardless of treatment path — gets better results with temperature management, trigger avoidance, and dietary adjustments. The three-path comparison article ties the whole decision tree together.
Limitations Every Woman Should Know
This comparison has a limitation that matters: individual response varies more than any table can capture. The woman who gets zero relief from a 50 mcg patch but perfect relief from compounded estradiol cream is rare, but she exists. The woman who experiences crushing nausea from Veozah but thrives on gabapentin is real. The data in this table represents averages from clinical trials, and averages hide outliers.
The second limitation is that the insurance coverage column is a snapshot, not a guarantee. Formularies change quarterly. The cost article and treatment reviews page are updated more frequently than this hub can be, so check those for the current reality of what your specific plan covers.
The third limitation is access. None of these options help if you cannot find a clinician who prescribes them. The menopause specialist guide and online treatment article were written specifically to solve the “my doctor says it is not necessary” problem that blocks so many women from effective care.
One last thing — and this is the most important line in this entire comparison: the right treatment for you is the one that actually fixes your symptoms, keeps your risk profile acceptable, and fits your life. The hierarchy matters. The evidence matters. But your individual experience is the data point that overrides every study. If a treatment is working and the risks are manageable, keep taking it. If it is not working, switch. The comparison table gives you the map. You drive the car.